EA005976B1 - Хинолинил и бензотиазолил ppar-гамма модуляторы - Google Patents

Хинолинил и бензотиазолил ppar-гамма модуляторы Download PDF

Info

Publication number
EA005976B1
EA005976B1 EA200300078A EA200300078A EA005976B1 EA 005976 B1 EA005976 B1 EA 005976B1 EA 200300078 A EA200300078 A EA 200300078A EA 200300078 A EA200300078 A EA 200300078A EA 005976 B1 EA005976 B1 EA 005976B1
Authority
EA
Eurasian Patent Office
Prior art keywords
nmr
dmso
chloro
mhz
dichloro
Prior art date
Application number
EA200300078A
Other languages
English (en)
Russian (ru)
Other versions
EA200300078A1 (ru
Inventor
Лоуренс Р. МакДжи
Джонатан Б. Хаузе
Стивен М. Рабенстейн
Атсуси Хагивара
Нобору Фурукава
Хисаси Синкаи
Original Assignee
Туларик Инк.
Джапан Тобакко Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Туларик Инк., Джапан Тобакко Инк. filed Critical Туларик Инк.
Publication of EA200300078A1 publication Critical patent/EA200300078A1/ru
Publication of EA005976B1 publication Critical patent/EA005976B1/ru

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62Benzothiazoles
    • C07D277/68Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20Oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/36Sulfur atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62Benzothiazoles
    • C07D277/64Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62Benzothiazoles
    • C07D277/68Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D277/82Nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Photoreceptors In Electrophotography (AREA)
  • Quinoline Compounds (AREA)
  • Holo Graphy (AREA)
EA200300078A 2000-06-28 2001-06-27 Хинолинил и бензотиазолил ppar-гамма модуляторы EA005976B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21481000P 2000-06-28 2000-06-28
PCT/US2001/020756 WO2002000633A1 (en) 2000-06-28 2001-06-27 Quinolinyl and benzothiazolyl ppar-gamma modulators

Publications (2)

Publication Number Publication Date
EA200300078A1 EA200300078A1 (ru) 2003-08-28
EA005976B1 true EA005976B1 (ru) 2005-08-25

Family

ID=22800496

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200300078A EA005976B1 (ru) 2000-06-28 2001-06-27 Хинолинил и бензотиазолил ppar-гамма модуляторы

Country Status (25)

Country Link
EP (1) EP1296967B1 (enExample)
JP (1) JP4515026B2 (enExample)
KR (1) KR100771286B1 (enExample)
CN (1) CN1243741C (enExample)
AT (1) ATE327984T1 (enExample)
AU (2) AU7163701A (enExample)
BR (1) BRPI0112115B8 (enExample)
CA (1) CA2412723C (enExample)
CY (1) CY1105126T1 (enExample)
CZ (1) CZ302982B6 (enExample)
DE (1) DE60120163T2 (enExample)
DK (1) DK1296967T3 (enExample)
EA (1) EA005976B1 (enExample)
ES (1) ES2265435T3 (enExample)
HK (1) HK1052351B (enExample)
HU (1) HUP0301482A3 (enExample)
IL (2) IL153461A0 (enExample)
MX (1) MXPA02012708A (enExample)
NO (1) NO325448B1 (enExample)
NZ (1) NZ523229A (enExample)
PL (1) PL214670B1 (enExample)
PT (1) PT1296967E (enExample)
SK (1) SK288236B6 (enExample)
WO (1) WO2002000633A1 (enExample)
ZA (1) ZA200210283B (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7041691B1 (en) 1999-06-30 2006-05-09 Amgen Inc. Compounds for the modulation of PPARγ activity
US6653332B2 (en) 2000-05-03 2003-11-25 Tularik Inc. Combination therapeutic compositions and method of use
US20030171399A1 (en) 2000-06-28 2003-09-11 Tularik Inc. Quinolinyl and benzothiazolyl modulators
SE0102764D0 (sv) 2001-08-17 2001-08-17 Astrazeneca Ab Compounds
ES2443642T3 (es) 2001-09-14 2014-02-20 Amgen Inc. Compuestos de biarilo conectados
US6716842B2 (en) 2002-04-05 2004-04-06 Warner-Lambert Company, Llc Antidiabetic agents
AU2003248549B2 (en) 2002-05-24 2010-04-08 Millennium Pharmaceuticals, Inc. CCR9 inhibitors and methods of use thereof
US7227035B2 (en) 2002-11-18 2007-06-05 Chemocentryx Bis-aryl sulfonamides
US7741519B2 (en) 2007-04-23 2010-06-22 Chemocentryx, Inc. Bis-aryl sulfonamides
US7420055B2 (en) 2002-11-18 2008-09-02 Chemocentryx, Inc. Aryl sulfonamides
PT1798223E (pt) 2002-11-18 2011-10-17 Chemocentryx Inc Aril-sulfonamidas
GB0226931D0 (en) 2002-11-19 2002-12-24 Astrazeneca Ab Chemical compounds
CA2513092C (en) 2003-02-13 2011-11-01 Wellstat Therapeutics Corporation Compounds for the treatment of metabolic disorders
KR20060025132A (ko) * 2003-04-11 2006-03-20 더 유니버시티 오브 테네시 리서치 파운데이션 리소포스파티드산 유사체 및 신생내막 형성의 저해
JP4805552B2 (ja) * 2003-05-30 2011-11-02 武田薬品工業株式会社 縮合環化合物
CA2527691C (en) * 2003-05-30 2013-01-22 Takeda Pharmaceutical Company Limited Condensed ring compound
US7223761B2 (en) * 2003-10-03 2007-05-29 Amgen Inc. Salts and polymorphs of a potent antidiabetic compound
US20050288340A1 (en) * 2004-06-29 2005-12-29 Pfizer Inc Substituted heteroaryl- and phenylsulfamoyl compounds
US7544702B2 (en) 2004-08-12 2009-06-09 Amgen Inc. Bisaryl-sulfonamides
JP4651714B2 (ja) 2005-07-09 2011-03-16 アストラゼネカ アクチボラグ 糖尿病の治療においてglk活性化剤として使用するためのヘテロアリールベンズアミド誘導体
KR20080089453A (ko) 2006-01-25 2008-10-06 웰스태트 테러퓨틱스 코포레이션 물질대사 장애의 치료용 화합물
EP1976377A4 (en) 2006-01-25 2010-06-23 Wellstat Therapeutics Corp COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS
NZ570334A (en) 2006-02-02 2011-07-29 Wellstat Therapeutics Corp Compounds for the treatment of metabolic disorders
EP1996567B1 (en) * 2006-02-15 2013-09-18 AbbVie Inc. Novel acetyl-coa carboxylase (acc) inhibitors and their use in diabetes, obesity and metabolic syndrome
PT2094663E (pt) * 2006-09-21 2011-04-19 Piramal Life Sciences Ltd Derivados de piridina para o tratamento de desordens metabólicas relacionadas com resistência à insulina ou hiperglicemia
WO2012162463A1 (en) * 2011-05-25 2012-11-29 Janssen Pharmaceutica Nv Benzothiazolyl inhibitors of pro-matrix metalloproteinase activation
WO2016144862A1 (en) 2015-03-09 2016-09-15 Intekrin Therapeutics, Inc. Methods for the treatment of nonalcoholic fatty liver disease and/or lipodystrophy
CN110996951A (zh) 2017-04-03 2020-04-10 科赫罗斯生物科学股份有限公司 治疗进行性核上性麻痹的PPARγ激动剂
CN109651208B (zh) * 2017-10-10 2022-01-04 中国科学院上海药物研究所 N-芳基磺酰胺类化合物,其药物组合物及其用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3632329A1 (de) * 1986-09-24 1988-03-31 Bayer Ag Substituierte phenylsulfonamide
CA2318731C (en) * 1998-01-29 2012-05-29 Tularik Inc. Ppar-gamma modulators
HK1043369B (en) * 1999-06-30 2014-06-13 日本烟草产业株式会社 Compounds for the modulation of ppar-gamma activity

Also Published As

Publication number Publication date
CA2412723C (en) 2010-12-14
HUP0301482A2 (hu) 2003-09-29
IL153461A (en) 2007-10-31
SK288236B6 (sk) 2015-01-07
IL153461A0 (en) 2003-07-06
DE60120163T2 (de) 2007-04-12
BR0112115A (pt) 2003-04-29
CA2412723A1 (en) 2002-01-03
KR20030024713A (ko) 2003-03-26
SK18352002A3 (sk) 2003-04-01
AU7163701A (en) 2002-01-08
CZ302982B6 (cs) 2012-02-01
DK1296967T3 (da) 2006-10-02
HUP0301482A3 (en) 2005-12-28
DE60120163D1 (de) 2006-07-06
ATE327984T1 (de) 2006-06-15
NO325448B1 (no) 2008-05-05
ES2265435T3 (es) 2007-02-16
ZA200210283B (en) 2005-09-28
NZ523229A (en) 2004-10-29
MXPA02012708A (es) 2003-09-22
AU2001271637B2 (en) 2006-05-04
EA200300078A1 (ru) 2003-08-28
HK1052351B (en) 2006-11-03
JP4515026B2 (ja) 2010-07-28
JP2004501905A (ja) 2004-01-22
EP1296967B1 (en) 2006-05-31
CY1105126T1 (el) 2010-03-03
PL214670B1 (pl) 2013-08-30
CZ20024197A3 (cs) 2003-06-18
KR100771286B1 (ko) 2007-10-29
CN1243741C (zh) 2006-03-01
CN1438998A (zh) 2003-08-27
BRPI0112115B1 (pt) 2016-07-26
PL359996A1 (en) 2004-09-06
EP1296967A1 (en) 2003-04-02
PT1296967E (pt) 2006-10-31
NO20026156L (no) 2003-02-25
NO20026156D0 (no) 2002-12-20
WO2002000633A1 (en) 2002-01-03
HK1052351A1 (en) 2003-09-11
BRPI0112115B8 (pt) 2021-05-25

Similar Documents

Publication Publication Date Title
EA005976B1 (ru) Хинолинил и бензотиазолил ppar-гамма модуляторы
US6583157B2 (en) Quinolinyl and benzothiazolyl modulators
US6770648B2 (en) Compounds for the modulation of PPARγ activity
AU2001271637A1 (en) Quinolinyl and benzothiazolyl ppar-gamma modulators
US7960408B2 (en) Quinolinyl and benzothiazolyl modulators
EA004887B1 (ru) СОЕДИНЕНИЯ, МОДУЛИРУЮЩИЕ АКТИВНОСТЬ PPARγ
US20050250820A1 (en) Therapeutic modulation of PPARgamma activity
AU6064300A (en) Compounds for the modulation of ppargamma activity

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM

MK4A Patent expired

Designated state(s): RU